5-hydroxy-2-(2-carboxy-6-methoxyphenyl)indole | 887645-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-hydroxy-2-(2-carboxy-6-methoxyphenyl)indole
• 英文别名: 2-(5-hydroxy-1H-indol-2-yl)-3-methoxybenzoic acid
• CAS: 887645-15-0
• 化学式: C₁₆H₁₃NO₄
• 分子量: 283.284
• InChiKey: JSRYVIQBCYYBOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  82.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-hydroxy-2-(2-carboxy-6-methoxyphenyl)indole 在 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以72%的产率得到4-methoxy-7-hydroxy-10H-isoindolo[2,1-a]indol-10-one
  参考文献：
  名称：

  New ligands at the melatonin binding site MT3

  摘要：

  The third melatonin binding site, MT3 is a non-classical one since it is not a seven transmembrane domains receptor, but an enzyme, quinone reductase 2. A major concern for the study of the physiological role of this site is the lack of specific ligands, permitting to more accurately dissect the pathways linked to the activation of MT3. Indeed, in the course of finding new ligands, we identified a new series of compounds with affinity to the binding site in the nM range, particularly 2,3-dimethoxy 7-hydroxy 10-methyl 5H 10H indeno(1,2-b)indol-10-one (DMHMIO), with a Ki of 190 pM. Based on slightly different and novel synthons compared to most of the compounds used in melatonin pharmacology studies, these compounds offer new perspective for the description of the melatonin pathways, so much more by not having any affinity towards the MTI and MT2 'classical' melatonin receptors. (c) 2006 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2005.12.002
• 作为产物：
  描述：

  4-甲氧基-2-苯并呋喃-1(3H)-酮 在 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 氢气 、 镍 、 三乙胺 作用下， 以 四氯化碳 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 90.0 ℃ 、506.62 kPa 条件下， 反应 20.25h， 生成 5-hydroxy-2-(2-carboxy-6-methoxyphenyl)indole
  参考文献：
  名称：

  New ligands at the melatonin binding site MT3

  摘要：

  The third melatonin binding site, MT3 is a non-classical one since it is not a seven transmembrane domains receptor, but an enzyme, quinone reductase 2. A major concern for the study of the physiological role of this site is the lack of specific ligands, permitting to more accurately dissect the pathways linked to the activation of MT3. Indeed, in the course of finding new ligands, we identified a new series of compounds with affinity to the binding site in the nM range, particularly 2,3-dimethoxy 7-hydroxy 10-methyl 5H 10H indeno(1,2-b)indol-10-one (DMHMIO), with a Ki of 190 pM. Based on slightly different and novel synthons compared to most of the compounds used in melatonin pharmacology studies, these compounds offer new perspective for the description of the melatonin pathways, so much more by not having any affinity towards the MTI and MT2 'classical' melatonin receptors. (c) 2006 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2005.12.002

文献信息

• New ligands at the melatonin binding site MT3
  作者：Marie-Françoise Boussard、Sandrine Truche、Anne Rousseau-Rojas、Sylvie Briss、Sophie Descamps、Monique Droual、Michel Wierzbicki、Gilles Ferry、Valérie Audinot、Philippe Delagrange、Jean A. Boutin

  DOI：10.1016/j.ejmech.2005.12.002

  日期：2006.3

  The third melatonin binding site, MT3 is a non-classical one since it is not a seven transmembrane domains receptor, but an enzyme, quinone reductase 2. A major concern for the study of the physiological role of this site is the lack of specific ligands, permitting to more accurately dissect the pathways linked to the activation of MT3. Indeed, in the course of finding new ligands, we identified a new series of compounds with affinity to the binding site in the nM range, particularly 2,3-dimethoxy 7-hydroxy 10-methyl 5H 10H indeno(1,2-b)indol-10-one (DMHMIO), with a Ki of 190 pM. Based on slightly different and novel synthons compared to most of the compounds used in melatonin pharmacology studies, these compounds offer new perspective for the description of the melatonin pathways, so much more by not having any affinity towards the MTI and MT2 'classical' melatonin receptors. (c) 2006 Elsevier SAS. All rights reserved.